Table S3 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

Table S3 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

<p>Gene mutation analysis identified in 50 patients with PanNETs</p>

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Junfeng Xu (16437141) (author)
Άλλοι συγγραφείς:	Zeng Ye (16437144) (author), Qifeng Zhuo (16437147) (author), Heli Gao (16437150) (author), Yi Qin (15400233) (author), Xin Lou (16437153) (author), Wuhu Zhang (16437156) (author), Fei Wang (16437159) (author), Yan Wang (16437162) (author), Desheng Jing (16437165) (author), Guixiong Fan (16437168) (author), Yue Zhang (16437171) (author), Xuemin Chen (16437174) (author), Jie Chen (16437177) (author), Xiaowu Xu (16437180) (author), Xianjun Yu (16437183) (author), Shunrong Ji (16437186) (author)
Έκδοση:	2025
Θέματα:	Cancer Cancer Biology Clinical Research and Trials Endocrine-Related Cancers Oncogenes & Tumor Suppressors Precision Medicine Rare Cancers
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια

Table S2 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression
ανά: Junfeng Xu (16437141)
Έκδοση: (2025)

Supplementary Data from β-Catenin–Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer
ανά: Dipika R. Mohan (15011204)
Έκδοση: (2025)

Figure 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
ανά: Clare Vesely (505402)
Έκδοση: (2025)

Figure 2 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
ανά: Clare Vesely (505402)
Έκδοση: (2025)

Figure 3 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
ανά: Clare Vesely (505402)
Έκδοση: (2025)

Figure 4 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
ανά: Clare Vesely (505402)
Έκδοση: (2025)

Figure 5 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
ανά: Clare Vesely (505402)
Έκδοση: (2025)

Table 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
ανά: Clare Vesely (505402)
Έκδοση: (2025)

Supplementary Tables from Biallelic <i>Dicer1</i> Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of <i>DICER1</i> Syndrome–Associated Cancer
ανά: Yemin Wang (17315078)
Έκδοση: (2025)

Supplementary fig 1 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
ανά: Jiwei Bai (15051797)
Έκδοση: (2025)

Supplementary fig 2 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
ανά: Jiwei Bai (15051797)
Έκδοση: (2025)

Supplementary fig 3 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
ανά: Jiwei Bai (15051797)
Έκδοση: (2025)

Supplementary fig 4 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
ανά: Jiwei Bai (15051797)
Έκδοση: (2025)

Supplementary fig 5 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
ανά: Jiwei Bai (15051797)
Έκδοση: (2025)

Table S1-S5 from Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
ανά: Jiwei Bai (15051797)
Έκδοση: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
ανά: Dwight H. Owen (15034782)
Έκδοση: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
ανά: Dwight H. Owen (15034782)
Έκδοση: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
ανά: Dwight H. Owen (15034782)
Έκδοση: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
ανά: Dwight H. Owen (15034782)
Έκδοση: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
ανά: Dwight H. Owen (15034782)
Έκδοση: (2025)

Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
ανά: Evangeline R. Jackson (15558808)
Έκδοση: (2025)

العمل بالأكثر والغالب عند الأصوليين: دراسة تطبيقية
ανά: Al-mutiri, Aloush Khaled
Έκδοση: (2022)

Figure S7 from LncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
ανά: Shiyi Yu (17079079)
Έκδοση: (2025)

Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
ανά: Gwo Yaw Ho (14961416)
Έκδοση: (2025)

Spreadsheet index of named bookbinders in the Sotheby's auction catalogues for the sales of the Major John Roland Abbey collection, sold between 1965 and 1989
ανά: John Hodgson (22668215)
Έκδοση: (2025)

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
ανά: Alyssa C. Flint (16676029)
Έκδοση: (2025)

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
ανά: Alyssa C. Flint (16676029)
Έκδοση: (2025)

Video 1_Imaging-driven diagnosis of retroperitoneal psoas major alveolar soft part sarcoma: a case report.mp4
ανά: Shasha Wei (1555588)
Έκδοση: (2025)

Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
ανά: Laura Boucai (15054310)
Έκδοση: (2025)

Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
ανά: Laura Boucai (15054310)
Έκδοση: (2025)

Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
ανά: Laura Boucai (15054310)
Έκδοση: (2025)

Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
ανά: Laura Boucai (15054310)
Έκδοση: (2025)

Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
ανά: Laura Boucai (15054310)
Έκδοση: (2025)

Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
ανά: Laura Boucai (15054310)
Έκδοση: (2025)

Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
ανά: Laura Boucai (15054310)
Έκδοση: (2025)

Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
ανά: Laura Boucai (15054310)
Έκδοση: (2025)

Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
ανά: Laura Boucai (15054310)
Έκδοση: (2025)

Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
ανά: Laura Boucai (15054310)
Έκδοση: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
ανά: John A. Ligon (15024477)
Έκδοση: (2025)

Supplementary file 1_Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.docx
ανά: Xiaohu Jin (9618675)
Έκδοση: (2025)

Cannot write session to /tmp/vufind_sessions/sess_he8fdprohtm0e49l2jqr4g1s1b